

26 January 2017 EMA/126130/2017

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product	
Humira/ adalimumab	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s)in the Community	See Annex A
Register of Medicinal Products:	

Marketing Authorisation Holder (MAH):		
Name and address of the MAH:	AbbVie Ltd. Abbott House Vanwall Business Park Vanwall Road	
	Maidenhead, Berkshire SL6 4UB UNITED KINGDOM	

Procedure	
Procedure number:	EMEA/H/C/000481/II/0158

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

-the development of this product has complied with all measures in the agreed paediatric investigation plan P/0324/2013. All studies in the agreed paediatric investigation plan P/0324/2013 were conducted after the entry into force of that Regulation,

-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan P/0324/2013 is included in the technical dossier.

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.